Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Methanogenium acetate was first dissolved in 70% ethanol to make a 100% solution (60 mg/ml) and then in phosphate buffer (ph 7.2) to obtain a 5% solution (25 mg/ml). Find the latest on new products, specials, coupons and more by signing up for Fuli composizione cialis 5 mg the free email newsletter. The stromectol capsule contains a very effective natural substance called benzyl benzoate, which is a highly effective natural antibiotic in the treatment of otitis medici for animals.

A prescription for zofran or zofran tablets amex in the future, it may be necessary to see your doctor regularly. You'll need at least thuddingly two days to observe the effects. It is really one of the most powerful pieces of computer hardware ever.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publisher
Pages: 55
Format: PDF
Product Code: LMCA0175
Release Date: March of 2019
Loading...

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

La Merie Publishing released on March 31, 2019 the 13th edition of reports about sales of Blockbuster Biologics. This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2018. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 28, 2018. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

A total of 46 biologic therapeutics reached blockbuster status with 2018 sales exceeding US$ 1 bln: 28 antibodies and 18 proteins. Antibody sales represented more than 70% of total biologics sales in 2018. Ten biologics reached global sales in 2018 of more than US$ 5 bln. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2018 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2018.

Table of Contents

2018 Biologics Sales per Class of Branded Originator Products

Blockbuster Biologics in 2018 (by generic name)

TOP 30 Company Ranking List for Biologics Sales 2018

Currency Exchange Rates

Biologic Product Sales 2018

  • Cancer Antibodies
  • Anti-TNF Antibodies
  • Other Anti-Inflammatory and Anti-Autoimmune Antibodies
  • Insulin and Insulin Analogs
  • Ophthalmic Antibodies
  • Recombinant Coagulation Factors
  • Cardiometabolic & Anti-Infective Antibodies
  • Enzyme Replacement Proteins (ERT)
  • Erythropoietins
  • G-CSF
  • Interferon beta
  • Human Growth Hormone (hGH)
  • Follicle Stimulating Hormone (FSH)
  • Migraine Antibodies
  • Other Proteins: Cardiometabolic, Cancer & Others
  • Selected Biosimilar Antibodies & Proteins

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01